Findings

What do systematic reviews say?

26 questions · 27 findings · 3 reviews · Common Mental Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 9 · 33.3%GRADE not reported 0 · 0%Very low 3 · 11.1%Low 10 · 37%Moderate 4 · 14.8%High 1 · 3.7%

S‐adenosyl methionine as monotherapy vs tricyclic antidepressants (TCAs)

Depression remission · depression in adults

The review found no eligible studies for this question.

1 finding from 1 review

S‐adenosyl methionine (SAMe) for depression in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Augmentation of current antidepressant (SSRI) with ziprasidone (40 mg/d to 160 mg/d) vs augmentation of current antidepressant (SSRI) with placebo or continue on SSRI monotherapy

Depressive symptoms · treatment‐resistant depression in adults

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 199 participants
Moderate

Augmentation of current antidepressant (SSRI) with ziprasidone (40 mg/d to 160 mg/d) vs augmentation of current antidepressant (SSRI) with placebo or continue on SSRI monotherapy

Dropouts ‐ Any dose · treatment‐resistant depression in adults

Augmentation of current antidepressant (SSRI) with ziprasidone (40… probably leads to higher dropouts ‐ Any dose compared with augmentation of current antidepressant (SSRI) with placebo or… (moderate certainty).

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
RR 1.6 [1.01, 2.55]
2 studies · 199 participants
Moderate

Augmentation of current antidepressant (SSRI) with ziprasidone (40 mg/d to 160 mg/d) vs augmentation of current antidepressant (SSRI) with placebo or continue on SSRI monotherapy

Response (≥ 50% reduction in MADRS or HAM‐D score) ‐ Any dose · treatment‐resistant depression in adults

Augmentation of current antidepressant (SSRI) with ziprasidone (40… probably leads to higher response (≥ 50% reduction in MADRS/HAM‐D score) ‐ Any dose compared with augmentation of current antidepressant (SSRI) with placebo or… (moderate certainty).

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
RR 1.8 [1.07, 3.04]
2 studies · 199 participants
Moderate

Augmentation of current antidepressant (SSRI) with ziprasidone (40 mg/d to 160 mg/d) vs augmentation of current antidepressant (SSRI) with placebo or continue on SSRI monotherapy

Remission · treatment‐resistant depression in adults

Augmentation of current antidepressant (SSRI) with ziprasidone (40… showed no clear difference in remission (clinician‐rated) ‐ Any dose compared with augmentation of current antidepressant (SSRI) with placebo or… (moderate certainty).

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
OR 1.46 [0.75, 2.86]
2 studies · 199 participants
Moderate

Augmentation of current antidepressant (SSRI) with ziprasidone (40 mg/d to 160 mg/d) vs augmentation of current antidepressant (SSRI) with placebo or continue on SSRI monotherapy

Quality of life ‐ not measured · treatment‐resistant depression in adults

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found